<DOC>
	<DOCNO>NCT02555878</DOCNO>
	<brief_summary>The purpose study demonstrate rivaroxaban superior placebo reduce risk primary composite outcome define objectively confirm symptomatic low extremity proximal deep vein thrombosis ( DVT ) , asymptomatic low extremity proximal DVT , symptomatic upper extremity DVT , symptomatic non-fatal pulmonary embolism ( PE ) , incidental PE , venous thromboembolism ( VTE ) -related death ambulatory adult participant various cancer type receive systemic cancer therapy high risk develop VTE .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Rivaroxaban Venous Thromboembolism ( VTE ) Prophylaxis Ambulatory Cancer Participants</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , parallel-group , superiority study compare efficacy safety rivaroxaban placebo primary prophylaxis venous thromboembolism ( VTE ) ambulatory adult participant , various cancer type schedule initiate systemic cancer therapy . The study consist 3 Phases : Screening Phase ( 14 Days ) , double-blind treatment Phase ( 180 Days ) follow Phase ( 30 Days ) . The duration participation study participant approximately 32 week .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Have histologically confirm solid malignancy include limited : pancreas , lung , stomach , colon , rectum , bladder , breast , ovary , renal lymphoma ( hematologic ) , locally advanced metastatic disease Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Have Khorana thromboembolic risk Score great equal ( &gt; = ) 2 Creatinine clearance ( CrCl ) &gt; = 30 milliliter per minute ( mL/min ) Plan initiate systemic cancer therapy within plus minus ( + ) 1 week receive first dose study drug intention receive systemic cancer therapy doubleblind treatment period intend duration determine treat oncologist accord standard protocol clinical care Diagnosis primary brain tumor Known history brain metastasis Bleeding diathesis , hemorrhagic lesion , active bleeding , condition high risk bleed Hematologic malignancy exception lymphoma Platelet count le ( &lt; ) 50,000/millimeter^3 ( mm^3 ) , Life expectancy less equal ( &lt; = ) 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Venous thromboembolism</keyword>
</DOC>